By: ABRS- Academic Team
Introduction
Clinical trials depend on the coordinated work of professionals with different areas of expertise. Clinical monitoring, study start-up, regulatory affairs, data management, and pharmacovigilance each contribute to the execution of research activities. For sponsors managing multiple studies or expanding into different regions, determining how to organize these functions becomes an important operational decision.
Some organizations maintain extensive internal clinical research teams, while others rely on external service providers for selected activities. However, the choice is not limited to conducting every function internally or outsourcing the management of an entire clinical trial. A Functional Service Provider (FSP) model offers another approach.
An FSP model is a clinical research outsourcing arrangement in which a sponsor engages an external provider to support specific functions through qualified professionals and defined operational services. Depending on the agreement, these professionals may work within the sponsor’s systems, standard operating procedures (SOPs), and governance structure while performing their assigned responsibilities.
A 2023 analysis published in Applied Clinical Trials, Outsourcing Model Usage and its Relationship to Clinical Trial Performance, distinguishes functional outsourcing from full-service arrangements, in which a Contract Research Organization (CRO) typically assumes responsibility for a broader range of study activities. The authors also explain that outsourcing structures frequently combine characteristics of different models, making it necessary to evaluate how responsibilities are distributed in practice.
Understanding an FSP model therefore requires examining how the arrangement is established and implemented. The process can be explained through six practical steps, beginning with the identification of functional needs and continuing through resource integration, clinical execution, and ongoing oversight.
Defining Functional Needs and Establishing Responsibilities
The first step in implementing an FSP model is identifying which clinical research functions require additional support.
A sponsor may have an established clinical operations department but need additional Clinical Research Associates (CRAs) to monitor investigative sites across several countries. Another sponsor may have sufficient monitoring capacity but require specialized personnel for regulatory submissions, safety activities, or clinical data management.
These requirements can vary depending on the number of studies, therapeutic areas, geographic coverage, available internal resources, and the complexity of the clinical development program. Rather than outsourcing an entire study, the sponsor can identify the specific functions for which external expertise or additional capacity is appropriate.
In the 2021 publication Vendor Selection & Management, published in the Journal of the Society for Clinical Data Management, Amatya and Edgerton describe how functional outsourcing can involve transferring selected activities to service providers while retaining other responsibilities internally. They emphasize the importance of defining expected services and deliverables before selecting a vendor.
The second step is establishing the scope of the FSP arrangement and documenting the responsibilities of the parties involved.
This includes determining which activities will be performed by the provider, which decisions remain with the sponsor, how professionals will report their work, and how operational issues will be communicated or escalated. The agreement may also address resource allocation, training expectations, performance measures, and the procedures applicable to the assigned functions.
These arrangements have important regulatory implications. The ICH E6(R3) Good Clinical Practice guideline establishes in Section 3.3 that sponsors should determine roles and allocate trial-related activities before their initiation. Section 3.6.4 further specifies that activities transferred to and assumed by a service provider should be documented in an agreement, while activities not specifically transferred remain with the sponsor.
For clinical investigations governed by the relevant United States regulations, 21 CFR § 312.52 addresses the written transfer of sponsor obligations to a CRO and the regulatory responsibilities associated with those transferred obligations.
These provisions demonstrate that an FSP relationship involves more than assigning external personnel to a clinical program. It requires an operational structure in which functional responsibilities, decision-making authority, and accountability are clearly understood.
Integrating Qualified Professionals Into Clinical Trial Operations
Once the functional requirements and responsibilities have been established, the third step is selecting appropriately qualified professionals and integrating them into the sponsor’s operational environment.
The qualifications required depend on the activities being assigned. Clinical monitoring personnel may need experience with particular therapeutic areas, study phases, or regional research environments. Regulatory professionals may require knowledge of country-specific submission requirements, while pharmacovigilance personnel need competencies appropriate to their assigned safety-related activities.
Section 3.4 of ICH E6(R3) addresses the use of appropriately qualified individuals throughout the trial process. Section 3.6.7 also places responsibility on the sponsor to assess the suitability of service providers for the activities they will undertake.
After professionals are selected, integration may involve familiarization with the protocol, training on relevant SOPs, access to authorized clinical systems, and clarification of reporting and escalation procedures. These activities help ensure that external professionals understand both their functional responsibilities and the sponsor’s expectations.
The fourth step is the execution of the assigned clinical trial activities.
Consider a hypothetical multinational clinical trial involving investigative sites in North America, Latin America, and Europe. The sponsor maintains responsibility for its clinical development strategy and overall trial governance but requires additional monitoring resources across these regions.
Under an FSP arrangement, qualified CRAs may be assigned to support the study. Their activities could include conducting monitoring visits, reviewing study documentation and data as specified in the monitoring plan, following up on findings, and communicating relevant issues to the designated sponsor team.
These professionals may work directly within the sponsor’s clinical trial management systems and established procedures. Their activities are coordinated with internal clinical operations personnel, allowing the sponsor to maintain visibility into the work being performed.
Other functions may follow a similar structure. Study start-up specialists may support site activation activities, regulatory professionals may contribute to submission preparation and documentation management, and pharmacovigilance professionals may perform assigned safety information processing activities.
The specific allocation of work depends on the service agreement and applicable requirements. Not every FSP provider performs all these functions, and the presence of several functions within one arrangement does not eliminate the need for clear operational boundaries.
The central principle is that external professionals contribute specialized capabilities within a defined clinical operating structure. Their integration should support collaboration without creating uncertainty about responsibilities or decision-making authority.
Maintaining Sponsor Oversight and Adapting Functional Support
Once FSP professionals begin performing their assigned activities, the fifth step is maintaining appropriate oversight and evaluating operational performance.
An FSP arrangement should include mechanisms that allow the sponsor and provider to understand whether the agreed activities are being performed according to expectations. Depending on the function, this may involve reviewing deliverables, assessing documentation quality, following up on monitoring findings, evaluating training completion, and tracking relevant performance indicators.
The level and nature of oversight should reflect the importance and risks associated with the assigned activities. For example, the oversight required for activities directly affecting participant safety or critical trial data may differ from that appropriate for routine administrative support.
The ICH E6(R3) guideline provides a relevant framework. Section 3.6.6 establishes that the sponsor retains ultimate responsibility for its trial-related activities, including participant protection and the reliability of trial data, even when activities are transferred to service providers. Sections 3.6.8 and 3.6.9 address access to relevant service-provider information and appropriate oversight of important transferred activities, including subcontracted work.
Similarly, Amatya and Edgerton, in Vendor Selection & Management, discuss the importance of governance arrangements, defined expectations, and risk-based vendor oversight.
The sixth step is evaluating whether the FSP arrangement continues to meet the evolving requirements of the clinical program.
A sponsor may need additional professionals when a study expands into new countries, activates more investigative sites, or introduces activities through protocol amendments. Conversely, the transition from active recruitment to study closeout may change the number or type of resources required.
An FSP structure can provide a mechanism for adjusting functional support, although the ability to make such changes depends on personnel availability, contractual arrangements, qualification requirements, and operational continuity planning. Significant changes to transferred activities may also require updates to the relevant agreements.
This is where the distinction between an FSP model and a simple staffing arrangement becomes particularly important. An effective functional partnership requires more than identifying available professionals. It also involves integrating the appropriate capabilities into an operational structure that supports communication, quality expectations, and accountability throughout the clinical trial lifecycle.
At Advanced BioResearch Solutions (ABRS), the FullSpectrum FSP model is designed around this approach. It provides functional support tailored to sponsor and CRO requirements, including clinical monitoring, study start-up, regulatory affairs, pharmacovigilance, and other specialized clinical research activities.
The model emphasizes integration with sponsor teams, regional expertise, resource flexibility, and structured operational governance. Within this framework, ABRS’s Clinical Oversight Management (COM) capabilities can also contribute to performance visibility, risk identification, and coordination of monitoring-related oversight activities, according to the agreed scope of services.
For sponsors managing clinical programs across different regions, the relevance of this approach lies in connecting specialized expertise with the processes and responsibilities already established for the study.
Rather than replacing sponsor governance, the FSP provider contributes functional capabilities that can be coordinated within the sponsor’s broader clinical operations strategy.
Conclusion:
A Functional Service Provider model is a structured approach to clinical research outsourcing that allows sponsors to obtain specialized operational support without necessarily transferring the management of an entire clinical trial.
Its implementation begins with identifying the functions that require additional resources and defining the responsibilities assigned to the service provider. Qualified professionals are then selected, integrated into the sponsor’s operating environment, and assigned to perform the relevant clinical research activities. Throughout execution, the relationship requires appropriate oversight, communication, and adjustments when operational needs change.
For sponsors, understanding these steps is important when evaluating whether functional outsourcing aligns with their internal capabilities, clinical development objectives, and governance requirements. An FSP model may offer flexibility and access to specialized expertise, but these potential advantages depend on the quality of implementation and the suitability of the arrangement for the specific program.
Within ABRS’s FullSpectrum FSP approach, the emphasis is on connecting qualified clinical research professionals with sponsor-led operations through defined responsibilities, functional integration, and structured oversight.
Ultimately, the value of an FSP model is not determined solely by the number of professionals assigned to a study. It depends on whether those professionals can perform the required activities effectively, work within the established operating structure, and contribute to clinical trial execution while preserving clear accountability.
An FSP model is therefore best understood not simply as an outsourcing solution, but as a framework for organizing specialized clinical research capabilities around the operational needs of the sponsor.